In BALB/c mouse models of Salmonella enterica serovar Typhimurium infection, a single oral immunization with a mutant strain with an insertion of the chloramphenicol resistance gene into the ATP-dependent protease clpP or lon gene decreased the number of salmonellae in each tissue sample 5 days after oral challenge with virulent S. Typhimurium at weeks 26 and 54 postimmunization. These data suggested that an oral immunization with the ClpP-or Lon-disrupted S. Typhimurium strain could provide long-term protection against oral challenge with virulent S. Typhimurium. Accordingly, recombinant oral non-typhoidal Salmonella (NTS) vaccines were constructed by incorporating mutants of both S. Typhimurium and S. enterica serovar Enteritidis harbouring stable in-frame markerless deletions of the clpP-lon-sulA (suppressor of lon), lonsulA or lon-msbB (acyltransferase) genes. Amongst these orally administered vaccine candidates, those with the lon-sulA gene deletion mutants of S. Typhimurium and S. Enteritidis protected BALB/c and C57BL/6J mice against oral challenge with both virulent S. Typhimurium and virulent S. Enteritidis. Therefore, the in-frame markerless lon-sulA gene deletion mutant of S. Typhimurium or S. Enteritidis could be a promising cross-protective NTS live vaccine candidate for practical use in humans.
INTRODUCTION
The non-typhoidal Salmonella (NTS) enterica serovars Typhimurium and Enteritidis, which are classified by the antigenic variability at LPS moieties (O antigens), flagellar (H) antigens and capsular polysaccharides (Vi antigens), are the two most important serovars of salmonellosis transmitted from animals to humans (Rabsch et al., 2001; Simon et al., 2011a) . Notably, 75-95 % of invasive NTS infections in young children in sub-Saharan Africa are due to S. Typhimurium and S. Enteritidis (Simon et al., 2011a) . In sub-Saharan Africa, high-risk hosts of NTS include young children and human immunodeficiency virus-infected individuals, and case fatality rates in both groups are~20-25 % (MacLennan & Levine, 2013) . As systemic salmonellosis has become increasingly difficult to treat with antibiotics due to rising resistance to fluoroquinolones and cephalosporins, prevention with vaccines is hampered by only moderate levels and limited duration of protection (Bumann, 2014) . However, no licensed vaccines against human NTS infections have yet been developed. Live attenuated Salmonella strains offer important advantages, such as low production costs and oral administration, and were first developed as vaccines to prevent disease caused by Salmonella infections in humans and livestock (Germanier & Füer, 1975; Stocker et al., 1983; Hassan & Curtiss, 1990) . Highly susceptible mouse models are suitable to assess the efficacy of NTS vaccines intended for human use (Simon et al., 2011a) . The ideal live Salmonella vaccine should harbour multiple defined mutations in known virulence genes that would render it safe regardless of the immunological status of the vaccine, but that would not result in excessive attenuation or loss of immunogenicity (Mastroeni & Ménager, 2003) .
Salmonella has two functionally distinct type III secretion systems encoded by Salmonella pathogenicity islands 1 and 2 (SPI-1 and -2) that translocate bacterial effector proteins into host cells. The effector proteins act to manipulate central host functions (Fass & Groisman, 2009; McGhie et al., 2009; Ramos-Morales, 2012) . It was recently reported that the combination of SPI-1-lon and SPI-1-lon-fliC (flagellin) mutations of S. Enteritidis resulted in an attenuated but immunogenic mutant suitable for the oral immunization of poultry (Matulova et al., 2013) . Meanwhile, we previously observed significant increases in the amount of S. Typhimurium LPS-specific secretory IgA (sIgA) in intestinal lavage fluid and in the number of S. Typhimurium LPS-specific sIgA-producing cells in lamina propria lymphocytes in mice following an oral immunization with CS2022 (Lon protease-deficient S. Typhimurium) or CS2007 (ClpP protease-deficient S. Typhimurium). In addition, an abundance of anti-S. Typhimurium LPS-specific sIgA on the intestinal mucosal surfaces has been shown to lead to the complete eradication of salmonellae in the intestinal epithelia after oral challenge with virulent S. Typhimurium (Matsui et al., 2003; Kodama et al., 2005) .
The present study was designed to evaluate the long-term protective immunity in BALB/c mice induced by a single oral immunization with CS2007 or CS2022. We also evaluated the cross-protective immunity in BALB/c and C57BL/6J mice induced by a single oral immunization of S. Typhimurium or S. Enteritidis mutants with in-frame markerless deletions of two or three genes, including lon, against a subsequent oral challenge with virulent S. Typhimurium or S. Enteritidis.
METHODS
Bacterial strains, media and growth conditions. The relevant bacterial strains and plasmids are listed in Table 1 . S. Typhimurium and S. Enteritidis strains were routinely grown in L-agar or L-broth (Difco and BBL) at 37 uC, supplemented with antibiotics at the following concentrations as appropriate: ampicillin (100 mg ml 21 ), chloramphenicol (30 mg ml 21 ), kanamycin (40 mg ml 21 ), nalidixic acid (25 mg ml 21 ) and tetracycline (15 mg ml 21 ).
Construction of targeted gene deletions. Insertion of an FRT (Flp recombination target)-flanked chloramphenicol or kanamycin resistance marker cassette (KD3 or KD4, respectively) into lon, sulA (suppressor of lon), msbB (acyltransferase) or clpP on the chromosome of S. Typhimurium LT2 (x3000 and x3477) was accomplished by lRed-mediated recombination (Datsenko & Wanner, 2000) . The PCR products of lon : : KD3 and lon : : KD4, sulA : : KD3 and sulA : : KD4, msbB : : KD3 and msbB : : KD4 or clpP : : KD3 and clpP : : KD4 were introduced into MS101 and MS102 using each primer pair and template DNA (pKD3 and pKD4) in order to construct gene replacement strains of S. Typhimurium LT2. The lon : : KD3 and lon : : KD4, sulA : : KD3 and sulA : : KD4, msbB : : KD3 and msbB : : KD4 or clpP : : KD3 and clpP : : KD4 strains of S.
Typhimurium x3181 and S. Enteritidis HY-1 were generated by bacteriophage P22 transduction (Schmieger, 1972) . The KD3 and KD4 cassettes were then disrupted in Salmonella strains by the Flp recombinase-excision method (Cherepanov & Wackernagel, 1995) . Finally, the lon, sulA, msbB and clpP double-or triple-gene-deleted combinations in S. Typhimurium x3181 and S. Enteritidis HY-1 were constructed by repeated P22 transduction and Flp recombination. The target gene deletions were checked by PCR using the mutationtesting primer pairs followed by DNA sequencing. The PCR primer sequences are listed in Table 2 .
Immunization and challenge. Both BALB/c and C57BL/6 mice possess a nramp1 (natural resistance-associated macrophage protein 1; also called Slc11A1, ity, bcg and lsh) gene, but they do not express a mature functional Nramp1 protein. Thus, BALB/c and C57BL/6 mice are susceptible to NTS infection due to their lower secretion of proinflammatory cytokines in addition to their massive infiltration of neutrophils and macrophages compared with the WT Nramp1 strains of mice (Valdez et al., 2009) . For inoculation with the vaccine strains, 7-to 10-week-old female BALB/c or C57BL/6J mice (Charles River Japan) were orally administered 1610 8 c.f.u. of exponential-growthphase salmonellae concentrated in 20 ml doses mixed with PBS containing 0.01 % (w/v) gelatine, pH 7.4 (BSG) (Matsui et al., 2003; Kodama & Matsui, 2004; Kodama, et al., 2005) . To determine the extent of bacterial clearance, we orally challenged immunized mice with virulent NTS strains at a dose of 5610 8 c.f.u. This infection dose of S. Typhimurium x3456 was~1600 times the LD 50 for BALB/c mice and~14 000 times the LD 50 for C57BL/6J mice (Kodama et al., 2005) . Five days later, the spleen, mesenteric lymph nodes (MLNs), Peyer's patches (PPs) and caecum were removed, homogenized, diluted in BSG, and plated to facilitate the enumeration of c.f.u. (Matsui et al., 2003; Kodama & Matsui, 2004; Kodama et al., 2005) . All mice were bred in the animal facility at the Kitasato Institute and all mouse experiments were performed in accordance with the institutional guidelines under an approved protocol.
ELISA. We used ELISA to detect the amount of anti-S. Typhimurium LPS-specific IgG in the serum and sIgA in the bile or intestinal lavage fluid. Naive (unimmunized) mice were used as negative controls. Each value was obtained by subtracting the mean value for the negative controls from the value for the immunized mice, as described previously (Matsui et al., 2003) .
Statistics. Prism 6 (GraphPad) was used for the statistical analyses. The data were combined from two independent experiments using five mice from each group (n510). The survival rates were analysed using the Kaplan-Meier log-rank test. The mean values of different groups were examined using a two-tailed Student's t-test. P,0.05 was regarded as significant.
RESULTS
Long-term protective efficacy of an oral immunization with clpP-or lon-deficient S. Typhimurium against oral challenge with virulent S. Typhimurium A single oral immunization of BALB/c mice with CS2007 or CS2022 (Fig. 1a) induced anti-S. Typhimurium LPSspecific IgG in the serum and anti-S. Typhimurium LPSspecific sIgA in the intestinal lavage fluid was maintained at week 54 after oral immunization (Fig. 1b, c) . However, the SDs of antibody titres increased as the immunized mice grew older, possibly due to differences in the ageing process IP: 54.70.40.11
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N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 N a iv e C S 2 0 0 7 C S 2 0 2 2 amongst individual mice. The amount of anti-S. Typhimurium LPS-specific sIgA in the bile was not boosted by oral challenge with virulent S. Typhimurium at weeks 26 and 54 after oral immunization (Fig. 1d, e) . Nevertheless, although BALB/c mice in the naive (unimmunized) group challenged with virulent S. Typhimurium all died by day 10 after challenge, mice in the CS2007-or CS2022-immunized groups challenged with virulent S. Typhimurium showed 100 % survival. Indeed, the immunization resulted in a decrease in the bacterial loads of virulent S. Typhimurium in the spleen, MLNs and PPs of immunized BALB/c mice 5 days after challenge at weeks 26 and 54 after immunization (Fig. 1f, g ). However, the immunization did not significantly decrease the bacterial loads of virulent S. Typhimurium in the caecum at week 54 (P.0.05) (Fig.  1g) . These data suggested that the clpP or lon deletion was suitable for the vaccine trial with a single oral immunization, which induced a long-lasting local immune response in the intestinal tract, thereby suppressing the S. Typhimurium infection for 1 year after immunization.
Cross-protective efficacy of an oral immunization with double-and triple-gene deletion mutants of S. enterica, all including lon deletion, against oral challenge with virulent S. Typhimurium and S. Enteritidis
We constructed lon-sulA, lon-msbB and clpP-lon-sulA markerless in-frame deletions of S. Typhimurium and S. Enteritidis as oral vaccine candidates (Table 1) . We then examined the protective efficacy of a single oral immunization of these vaccine candidates by determining the survival rates for 60 days after oral challenge with virulent S. Typhimurium (x3181 or x3456) or S. Enteritidis (HY-1) in BALB/c and C57BL/6J mice (Fig. 2a ). There were no significant differences in mortality rates between the x3181 or x3456 and HY-1 challenges in the naive (unimmunized) BALB/c and C57BL/6J mice after oral challenges with 5610 5 c.f.u. (P.0.05). In addition, neither the S. Typhimurium vaccine candidates (MS305, MS306 and MS307) nor the S. Enteritidis vaccine candidates (MS405, MS406 and MS407) were recovered from the spleen, MLNs, PPs or caecum of BALB/c or C57BL/6J mice at day 28 after oral immunizations with 1610 8 c.f.u. In the first trial, a single oral immunization with the triple clpP-lonsulA deletion mutants of S. Typhimurium (MS307) or S. Enteritidis (MS407) conferred almost no protection to BALB/c mice against oral challenge with x3181 or HY-1 (Fig. 2b) . In the second trial, a single oral immunization with the double lon-sulA deletion mutants of both S. Typhimurium (MS305) and S. Enteritidis (MS405) protected BALB/c mice against oral challenge with x3181 or HY-1, although the level of protection conferred by MS305 against the oral challenge with HY-1 was low compared with the other three cases (Fig. 2c) . In the third trial, a single oral immunization with MS305 or MS405 protected both BALB/c and C57BL/6J mice against oral challenge with x3456 (Fig. 2d) . In the final trial, a single oral immunization with the double lon-msbB deletion mutants of S. Typhimurium (MS306) and S. Enteritidis (MS406) protected both BALB/c and C57BL/6J mice against oral challenge with x3456. However, the levels of protection conferred by MS406 in both BALB/c and C57BL/6J mice against the oral challenge with x3456 were lower than those achieved by MS305 (Fig. 2e) . These data suggested that the lon-sulA markerless in-frame deletion mutants of S. Typhimurium (MS305) and S. Enteritidis (MS405) were suitable as live vaccine strains for a single oral immunization trial against oral challenge with virulent S. Typhimurium and S. Enteritidis.
DISCUSSION
There are 50-200 promising protective antigens amongst the .4000 proteins encoded in Salmonella genomes; suitable protective antigens need to be surface-exposed to enable antibody binding, which substantially narrows down the number of potential candidates (Bumann, 2014) . In recent years, an increasing number of studies have demonstrated the effectiveness of membrane-anchored flagellin as a mucosal adjuvant, as well as its ability to promote cytokine expression by innate immune cells and trigger the generalized recruitment of T-and B-lymphocytes to secondary lymphoid organs (Mizel & Bates, 2010) . For instance, overexpression of flagella has been shown to enhance the induction of an antigen-specific immune response in macrophages and vaccination with a live attenuated strain of S. Typhimurium that produces two flagellin proteins (FliC and FljB) induced protective immune responses against oral challenge with virulent S. Typhimurium (Eom et al., 2013) . In addition, S. Enteritidis core and O polysaccharide-FliC glycoconjugates were immunogenic and protective antigens against intraperitoneal challenge with virulent S. Enteritidis in murine models, although the unconjugated NTS core and O polysaccharide were poor immunogens that did not elicit immunological memory (Simon et al., 2011b) . Furthermore, the passive transfer of immune sera from mice with S. Enteritidis core and O polysaccharide-FliC glycoconjugates to naive mice was also protective against intraperitoneal challenge with virulent S. Enteritidis, demonstrating the role of antibodies in mediating protection (Simon et al., 2013) .
Non-living Salmonella vaccines are thought to confer protection only in host-pathogen interactions that result in sublethal infection, such as in a challenge of resistant mice with either highly virulent or weakly virulent strains, or a challenge of susceptible mice with weakly virulent strains (Simon et al., 2011a) . However, protection by attenuated Salmonella vaccines is much more complicated, and is characterized by a delicate balance between virulence/ attenuation and inflammation/immunogenicity within the host. An oral immunization with CS2022 sufficiently induced T-cell-mediated immunity in mice (Eguchi et al., 2007a) and simultaneously induced immune tolerance correlated with the downregulation of cell surface Toll-like receptor expression in mice (Eguchi, et al., 2007b and CS2022 were detected in the tissues of BALB/c and C57BL/6J mice even at week 12 after an oral immunization (Matsui et al., 2003; Kodama et al., 2005) , indicating that salmonellae can colonize the intestinal tract, penetrate the lumen, and enter the lymphatic system and bloodstream, thereby maintaining long-term protective immunity in the immunized mice against oral challenge with virulent strains. In fact, an oral immunization with either CS2007 or CS2022 showed efficacy in protecting BALB/c mice against virulent S. Typhimurium infection 5 days after challenge at weeks 26 and 54 post-immunization (Fig. 1f,  g ), without the boost effect of oral challenge in the amounts of anti-S. Typhimurium LPS-specific sIgA in the bile (Fig. 1d, e) . Our previous studies have shown that although no significant increases in the amount of S. Typhimurium LPS-specific sIgA in the bile or intestinal lavage fluid occur following oral challenge in either CS2007-or CS2022-immunized BALB/c and C57BL/6 mice, both immunized mouse models can be protected against a subsequent oral challenge with virulent S. Typhimurium, with the result that virulent S. Typhimurium was not detected in any of the mouse tissue samples 5 days after oral challenge (Matsui et al., 2003; Kodama et al., 2005) . Orally infected salmonellae are unable to immediately enter a rapid growth phase, whereas IgA in mucosal secretions has an important function in the inhibition of bacterial penetration into the PPs (Cerutti et al., 2011) . Conversely, protection by circulating serum antibodies can potentially play a role in inhabiting the cell-to-cell transmission of Salmonella following exit from infected cells, as well as in a reduction in the overall systemic bacterial cell burden (Tsolis et al., 2011) . We speculate that an oral immunization with either CS2007 or CS2022 can achieve a sufficient level of S. Typhimurium LPS-specific sIgA in the intestinal lavage fluid to inhibit the bacterial penetration into the PPs for 1 year after oral immunization, as the immunization resulted in a decrease in the bacterial loads of virulent S. Typhimurium in the tissues 5 days after challenge at weeks 26 and 54 after immunization (Fig. 1f, g ).
In general, live attenuated Salmonella vaccines should not carry any antibiotic resistance markers if they are to be used in practical applications. Thus, we constructed inframe markerless deletion mutants that included lon deletion in both S. Typhimurium and S. Enteritidis. Bacterial cell division occurs through the formation of an FtsZ ring (Z ring) at the site of division, which is inhibited by SulA, a member of the SOS regulon and a specific target of the Lon protease, by binding to a polymerizationcompetent form of FtsZ in a 1 : 1 ratio (Lutkenhaus & Addinall, 1997) . The inhibition of FtsZ-mediated cell division by the expression of SulA induces a filamentous form of S. Typhimurium that is unable to invade epithelial cells (Humphrey et al., 2011) . LPS consists of three major components. Lipid A, with its fatty acid anchors (lauric, myristic and sometimes palmitic acid), is an endotoxin primarily responsible for TNF-a-mediated septic shock. The addition of myristic acid to the lipid A precursor is catalysed by MsbB (Clementz et al., 1997) . The Salmonella msbB mutants exhibit a reduced ability to stimulate the production of proinflammatory cytokines associated with septic shock and thus enhance the safety of the vaccines for human use (Alaniz et al., 2007) . Our present results show that although a single oral immunization with double lonsulA deletion mutants of S. Typhimurium (MS305) and S. Enteritidis (MS405) protected both BALB/c and C57BL/6J mice against oral challenge with virulent S. Typhimurium (x3181) or S. Enteritidis (HY-1), oral immunization with MS305 had less protective efficacy in BALB/c mice against oral challenge with HY-1 compared with those of other vaccine trials (Fig. 2c) . This is in part because a recent study showed that in a BALB/c mouse model of NTS infection, S. Enteritidis had greater numbers of serovarspecific virulence genes that were absent in the genome of S. Typhimurium (Silva et al., 2012) .
The paediatric invasive NTS infections in sub-Saharan Africa are clinically severe and accompanied by case fatality rates of~25 % (Rabsch et al., 2001; Simon et al., 2011a; MacLennan & Levine, 2013) . Murine salmonellosis is widely used in appropriate experimental models for developing NTS vaccines for human use (Rabsch et al., 2001; Simon et al., 2011a) . There is an urgent medical need for NTS vaccines with broad serovar coverage and high efficacy against systemic salmonellosis. MS305 and MS405 induced efficient cross-protection after a single oral immunization. Both strains appear to be practical live NTS vaccine candidates intended for human use in subSaharan Africa.
